Balyasny Asset Management
CLDX icon

Balyasny Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Balyasny Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$979K Sell
26,313
-58,713
-69% -$1.9M ﹤0.01% 2224
2026
Q1 		$2.7M Buy
+85,026
New +$2.32M ﹤0.01% 1652
2025
Q4 		– Sell
-11,632
Closed -$301K – 3141
2025
Q3 		$301K Buy
+11,632
New +$270K ﹤0.01% 2576
2024
Q4 		– Sell
-86,573
Closed -$2.94M – 2805
2024
Q3 		$2.94M Buy
+86,573
New +$3.3M ﹤0.01% 1500
2024
Q2 		– Sell
-64,769
Closed -$2.72M – 2631
2024
Q1 		$2.72M Buy
64,769
+40,650
+169% +$1.67M ﹤0.01% 1449
2023
Q4 		$957K Sell
24,119
-3,296
-12% -$96.9K ﹤0.01% 1707
2023
Q3 		$754K Buy
+27,415
New +$859K ﹤0.01% 1636
2022
Q2 		– Sell
-61,240
Closed -$2.09M – 2798
2022
Q1 		$2.09M Buy
61,240
+53,878
+732% +$1.72M 0.01% 1333
2021
Q4 		$284K Buy
+7,362
New +$321K ﹤0.01% 1756
2018
Q2 		– Sell
-5,187
Closed -$181K – 1815
2018
Q1 		$181K Buy
5,187
+3,147
+154% +$122K ﹤0.01% 1774
2017
Q4 		$87K Sell
2,040
-1,053
-34% -$45.1K ﹤0.01% 1984
2017
Q3 		$133K Buy
+3,093
New +$116K ﹤0.01% 1754
2015
Q3 		– Sell
-3,720
Closed -$1.41M – 1168
2015
Q2 		$1.41M Buy
+3,720
New +$1.48M 0.01% 771
2013
Q3 		– Sell
-18,333
Closed -$4.29M – 582
2013
Q2 		$4.29M Buy
+18,333
New +$3.61M 0.07% 321

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's CLDX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Celldex Therapeutics (CLDX) stake by 69% in Q2 2026, selling an estimated $1.9M and leaving 26,313 shares worth $979K. The position accounts for ﹤0.01% of the portfolio, ranked #2224.

Balyasny Asset Management first reported a position in CLDX in Q2 2013 and has held it in 14 quarters since. The position peaked at $4.29M in Q2 2013. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Balyasny Asset Management held 26,313 shares of Celldex Therapeutics worth $979K as of Q2 2026.
  • Balyasny Asset Management sold 58,713 Celldex Therapeutics shares in Q2 2026, an estimated $1.9M.
  • Celldex Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2224 holding.
  • Balyasny Asset Management first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 14 quarters since.
  • Balyasny Asset Management's Celldex Therapeutics position peaked at $4.29M in Q2 2013.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.